Drugs / Vanakizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07451665 | Apr 2026 → Mar 2029 expected | Takayasu arteritis | Chinese SLE Treatment And Research Group | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vanakizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07451665 ↗ |
| Route | Subcutaneous | “taken subcutaneously” NCT07451665 ↗ |